State of the ACTG
June, 2015

Daniel R. Kuritzkes, MD
Principal Investigator and Chair
AIDS Clinical Trials Group
Progress on ACTG Trials

- 4 studies completed follow-up
  - ACTG A5245 (HPTN 052)
  - ACTG A5273 (SELECT)
  - ACTG A5294 (boceprevir)
  - ACTG A5295 (GeneXprt)
Progress on ACTG Trials

- 7 studies completed accrual
  - ACTG A5274 (REMEMBER)
  - ACTG A5279 (rifapentine for TB prophylaxis)
  - ACTG A5305 (HPTN 069)
  - ACTG A5308 (ART for elite controllers)
  - ACTG A5322 (HIV infection, aging & inflammation)
  - ACTG A5331 (aspirin)
  - P1077HS (PROMISE)
Progress on ACTG Trials

- 5 studies opened to accrual
  - ACTG A5307 (essentially of INH)
  - ACTG A5312 (high-dose INH)
  - ACTG A5316 (PK of vaginal ring contraceptives and ART)
  - ACTG A5331 (aspirin)
  - ACTG A5342 (VRC-01 and the HIV reservoir)
ACTG Accrual (May, 2014 – April, 2015)

- 2400 enrolled into interventional trials*
  - 502 enrolled into observational studies
- 2902 total subjects enrolled across all studies
  *includes GI substudy

- 1865 patients enrolled at international sites
- 997 patients enrolled at US sites
- 40 patients enrolled at non-ACTG CRSs